Biosimilars A Driving Force Behind Korean Pharma Exports

Remsima/Inflectra's rapid penetration into global biosimilar markets is helping Celltrion to grow into a global biologics powerhouse and also boosting South Korea's pharma exports. The country has logged a biologics trade surplus for the first time in years, due mainly to a surge in exports of biosimilar infliximab, and trend only set to continue with more approvals and launches on the horizon.